C4 Therapeutics, Inc. (CCCC) Misses Q3 EPS by 3c
Tweet
Share
E-mailGet Alerts CCCC Hot Sheet
Join SI Premium – FREE
C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q3 EPS of ($0.44), $0.03 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $11.23 million versus the consensus estimate of $6.13 million.
For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- XP Inc. (XP) Tops Q2 EPS by 8c
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
